

(51) International Patent Classification 6 : A61K 38/46, 31/135, 31/46 // (A61K 31/135, 31:135)		A2	(11) International Publication Number: WO 98/22132
			(43) International Publication Date: 28 May 1998 (28.05.98)
(21) International Application Number: PCT/US97/21696		(74) Agents: KOHN, Kenneth, I. et al.; Kohn & Associates, Suite 410, 30500 Northwestern Highway, Farmington Hills, MI 48334 (US).	
(22) International Filing Date: 20 November 1997 (20.11.97)			
(30) Priority Data: 60/031,194 20 November 1996 (20.11.96) US 60/035,266 12 December 1996 (12.12.96) US 60/053,200 21 July 1997 (21.07.97) US		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(71) Applicant (for all designated States except US): YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM [IL/IL]; Jabotinsky Street 46, P.O. Box 4279, 91042 Jerusalem (IL).		Published Without international search report and to be republished upon receipt of that report.	
(71) Applicant (for MW only): KOHN, Kenneth, I. [US/US]; 6761 Alderly Way, West Bloomfield, MI 48322 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): SOREQ, Hermona [IL/IL]; HaMaayan Street_14, 95903 Jerusalem (IL). FRIEDMAN, Alon [IL/IL]; Moshav Maslul, 85112 M. Post HaNeguev (IL). SEIDMAN, Shlomo [IL/IL]; 90909 Neve Daniel (IL). KAUFER, Daniela [IL/IL]; Haguilboa Street_10/6, 90805 Mevasseret Zion (IL).			
(54) Title: A METHOD AND COMPOSITION FOR ENABLING PASSAGE THROUGH THE BLOOD-BRAIN BARRIER			
(57) Abstract  A pharmaceutical composition for facilitating passage of compounds through the blood-brain barrier comprising the agent ACHE-I4 readthrough (SEQ ID No:1) splice variant or the I4 peptide (SEQ ID No:2) and analogues of each thereof and a pharmaceutically acceptable carrier is disclosed. Alternatively, the pharmaceutical composition for facilitating passage of compounds through the blood-brain barrier can comprise the agents adrenaline, atropine, dopamine and/or an adrenergic combination and a pharmaceutically acceptable carrier. The composition can comprise at least two of the agents. The composition of the present invention can optionally include the compound to be transported across the blood-brain barrier. Alternatively, the compound can be co-administered (simultaneously) with the composition or can be administered at some point during the biologically effective period of the action of the composition. The present invention provides a method for administering a compound to the CNS of an animal by subjecting the animal to a stress-mimicking agent or treatment. This agent or treatment facilitates disruption of the blood-brain barrier. During the period that the BBB is opened or disrupted a compound can be administered such that the compound is enabled to pass through the disrupted BBB into the CNS.			



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification<sup>6</sup> : <b>A61K 38/46, 31/135, 31/46</b></p>	<p><b>A3</b></p>	<p>(11) International Publication Number: <b>WO 98/22132</b> (43) International Publication Date: <b>28 May 1998 (28.05.98)</b></p>									
<p>(21) International Application Number: <b>PCT/US97/21696</b> (22) International Filing Date: <b>20 November 1997 (20.11.97)</b>  (30) Priority Data:  <table border="0"> <tr> <td>60/031,194</td> <td>20 November 1996 (20.11.96)</td> <td>US</td> </tr> <tr> <td>60/035,266</td> <td>12 December 1996 (12.12.96)</td> <td>US</td> </tr> <tr> <td>60/053,200</td> <td>21 July 1997 (21.07.97)</td> <td>US</td> </tr> </table>  (71) Applicant (for all designated States except US): <b>YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM [IL/IL]; Jabotinsky Street 46, P.O. Box 4279, 91042 Jerusalem (IL).</b>  (71) Applicant (for MW only): <b>KOHN, Kenneth, I. [US/US]; 6761 Alderly Way, West Bloomfield, MI 48322 (US).</b>  (72) Inventors; and (75) Inventors/Applicants (for US only): <b>SOREQ, Hermona [IL/IL]; HaMaayan Street_14, 95903 Jerusalem (IL). FRIEDMAN, Alon [IL/IL]; Moshav Maslul, 85112 M. Post HaNeguev (IL). SEIDMAN, Shlomo [IL/IL]; 90909 Neve Daniel (IL). KAUFER, Daniela [IL/IL]; Haguilboa Street_10/6, 90805 Mevasseret Zion (IL).</b></p>		60/031,194	20 November 1996 (20.11.96)	US	60/035,266	12 December 1996 (12.12.96)	US	60/053,200	21 July 1997 (21.07.97)	US	<p>(74) Agents: <b>KOHN, Kenneth, I. et al.; Kohn &amp; Associates, Suite 410, 30500 Northwestern Highway, Farmington Hills, MI 48334 (US).</b>  (81) Designated States: <b>AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</b>  <b>Published</b> <b>With international search report.</b>  (88) Date of publication of the international search report: <b>17 September 1998 (17.09.98)</b></p>
60/031,194	20 November 1996 (20.11.96)	US									
60/035,266	12 December 1996 (12.12.96)	US									
60/053,200	21 July 1997 (21.07.97)	US									
<p>(54) Title: <b>A METHOD AND COMPOSITION FOR ENABLING PASSAGE THROUGH THE BLOOD-BRAIN BARRIER</b>  (57) Abstract   <p>A pharmaceutical composition for facilitating passage of compounds through the blood-brain barrier comprising the agent ACHE-I4 readthrough (SEQ ID No:1) splice variant or the I4 peptide (SEQ ID No:2) and analogues of each thereof and a pharmaceutically acceptable carrier is disclosed. Alternatively, the pharmaceutical composition for facilitating passage of compounds through the blood-brain barrier can comprise the agents adrenaline, atropine, dopamine and/or an adrenergic combination and a pharmaceutically acceptable carrier. The composition can comprise at least two of the agents. The composition of the present invention can optionally include the compound to be transported across the blood-brain barrier. Alternatively, the compound can be co-administered (simultaneously) with the composition or can be administered at some point during the biologically effective period of the action of the composition. The present invention provides a method for administering a compound to the CNS of an animal by subjecting the animal to a stress-mimicking agent or treatment. This agent or treatment facilitates disruption of the blood-brain barrier. During the period that the BBB is opened or disrupted a compound can be administered such that the compound is enabled to pass through the disrupted BBB into the CNS.</p> </p>											

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/21696

**A. CLASSIFICATION OF SUBJECT MATTER**  
 IPC 6 A61K38/46 A61K31/135 A61K31/46

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 414 568 A (WASHINGTON UNIVERSITY) 27 February 1991 see the whole document ---	3-16
A	WO 95 23158 A (YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSAL) 31 August 1995 see the whole document ---	1-17
A	EP 0 364 584 A (KI NII FARMAKOLOGII TOKSIKOLOG) 25 April 1990 see the whole document ---	1-17
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

15 May 1998

Date of mailing of the international search report

24.06.1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Moreau, J

## INTERNATIONAL SEARCH REPORT

Inter.      nal Application No

PCT/US 97/21696

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>FRIEDMAN, ALON ET AL: "Pyridostigmine brain penetration under stress enhances neuronal excitability and induces early immediate transcriptional response" NAT. MED. (N. Y.) (1996), 2(12), 1382-1385, XP002065074 see the whole document -----</p>	1-17

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 97/21696

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 6-16 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.  
Although claim 17 is directed to a diagnostic method practised on the
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

page 1 of 2

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 97/21696

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

page 2 of 2

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Although claims 6-16 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.  
Although claim 17 is directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.



# INTERNATIONAL SEARCH REPORT

Information on patent family members

Inten 181 Application No

PCT/US 97/21696

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 414568	A	27-02-1991	US 4988710 A	29-01-1991
			US 5011853 A	30-04-1991
WO 9523158	A	31-08-1995	AU 2096395 A	11-09-1995
			EP 0750627 A	02-01-1997
EP 0364584	A	25-04-1990	WO 8910124 A	02-11-1989

CORRECTED  
VERSION\*

CORRECTED  
VERSION\*\*

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 38/46, 31/135, 31/46</b>		<b>A3</b>	(11) International Publication Number: <b>WO 98/22132</b>
			(43) International Publication Date: <b>28 May 1998 (28.05.98)</b>
(21) International Application Number: <b>PCT/US97/21696</b>			(74) Agents: KOHN, Kenneth, I. et al.; Kohn & Associates, Suite 410, 30500 Northwestern Highway, Farmington Hills, MI 48334 (US).
(22) International Filing Date: <b>20 November 1997 (20.11.97)</b>			
(30) Priority Data:			
60/031,194                      20 November 1996 (20.11.96)      US			
60/035,266                      12 December 1996 (12.12.96)      US			
60/053,200                      21 July 1997 (21.07.97)      US			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(71) Applicant (for all designated States except US): YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL/IL); Jabotinsky Street 46, P.O. Box 4279, 91042 Jerusalem (IL).			
(71) Applicant (for MW only): KOHN, Kenneth, I. [US/US]; 6761 Alderly Way, West Bloomfield, MI 48322 (US).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): SOREQ, Hermona [IL/IL]; HaMaayan Street 14, 95903 Jerusalem (IL). FRIEDMAN, Alon [IL/IL]; Moshav Maslul, 85112 M. Post HaNeguev (IL). SEIDMAN, Shlomo [IL/IL]; 90909 Neve Daniel (IL). KAUFER, Daniela [IL/IL]; Haguilboa Street 10/6, 90805 Mevasseret Zion (IL).			
(88) Date of publication of the international search report: <b>17 September 1998 (17.09.98)</b>			
Published With international search report.			
(54) Title: A METHOD AND COMPOSITION FOR ENABLING PASSAGE THROUGH THE BLOOD-BRAIN BARRIER			
(57) Abstract			
<p>A pharmaceutical composition for facilitating passage of compounds through the blood-brain barrier comprising the agent ACHE-14 readthrough (SEQ ID No:1) splice variant or the I4 peptide (SEQ ID No:2) and analogues of each thereof and a pharmaceutically acceptable carrier is disclosed. Alternatively, the pharmaceutical composition for facilitating passage of compounds through the blood-brain barrier can comprise the agents adrenaline, atropine, dopamine and/or an adrenergic combination and a pharmaceutically acceptable carrier. The composition can comprise at least two of the agents. The composition of the present invention can optionally include the compound to be transported across the blood-brain barrier. Alternatively, the compound can be co-administered (simultaneously) with the composition or can be administered at some point during the biologically effective period of the action of the composition. The present invention provides a method for administering a compound to the CNS of an animal by subjecting the animal to a stress-mimicking agent or treatment. This agent or treatment facilitates disruption of the blood-brain barrier. During the period that the BBB is opened or disrupted a compound can be administered such that the compound is enabled to pass through the disrupted BBB into the CNS.</p>			

\* (Referred to in PCT-Gazette No. 26/1998, Section II) \*\* (Referred to in PCT-Gazette No. 42/1998, Section II)

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

A METHOD AND COMPOSITION FOR ENABLING  
PASSAGE THROUGH THE BLOOD-BRAIN-BARRIER

BACKGROUND OF THE INVENTION

5

1. FIELD OF THE INVENTION

The present invention relates to a method and composition for transporting compounds including pharmaceutical compositions across the Blood-Brain Barrier (BBB).

2. DESCRIPTION OF RELATED ART

15 The Blood-Brain Barrier (BBB) maintains a homeostatic environment in the central nervous system (CNS). The capillaries that supply the blood to the brain have tight junctions which block passage of most molecules through the capillary endothelial membranes. While the membranes do allow passage of lipid soluble materials, such as heroin and other psychoactive drugs, water soluble materials such as glucose, proteins and amino acids do not pass through the BBB. Mediated transport mechanisms exist to transport glucose and essential amino acids across the BBB. Active transport mechanisms remove molecules which become in excess, such as potassium, from the brain. For a general review see Goldstein and Betz, 1986 and Betz et al, 1994, incorporated herein in their entirety by reference.

25 The BBB was initially observed by Ehrlich when he observed what he termed "lower affinity" of vital dyes for the brain than other tissue. Goldmann in 1913 however, determined the actual presence of a barrier by showing that the vital dye trypan blue when injected directly into the brain stained the brain but did not

leave the CNS. These early experiments by Golmann and others established that the CNS is separated from the bloodstream by blood-brain and blood-cerebrospinal fluid (CSF) barriers.

5       The BBB impedes the delivery of drugs to the CNS. Methods have been designed to deliver needed drugs such as direct delivery within the CNS by intrathecal delivery can be used with, for example, an Ommaya reservoir. United States Patent 5,455,044 provides for use of a  
10       dispersion system for CNS delivery or see United States Patent 5,558,852 for a discussion of other CNS delivery mechanisms as well as Betz et al [1994] and Goldstein and Betz [1986].

15       There has been some progress in designing drugs that utilize the structure and function of the BBB itself to deliver the drugs. These drugs are designed to be lipid soluble or to be "piggy-backed" into the CNS by being coupled to peptides that can cross the BBB through mediated transport mechanisms. However, not all drugs  
20       are amenable to this solution. Partridge and his colleagues have worked extensively in this area. Pharmacological formulations that cross the blood-brain barrier can be administered. [Brem et al., 1993] Such formulations can take advantage of methods now available  
25       to produce chimeric peptides in which the present invention is coupled to a brain transport vector allowing transportation of these engineered drugs across the barrier [Partridge, et al., 1992; Partridge, 1992; Bickel, et al., 1993]. See also The Economist, January  
30       4, 1997.

35       In the disease process, the BBB is often disrupted. For example in meningitis, Tuomanen [1993] has shown that the response against the bacterial infection lead to a breach of the BBB. Further, in trauma and brain tumors the BBB is often disrupted as well as exposure to certain

agents such as soman [Lallement et al, 1991; Petrali et al, 1991]. Disruption has been shown in ischemia [Burst, 1991] and in Alzheimer's Disease [Harik and Kalaria, 1991].

5 In appropriate cases the blood-brain barrier disruption can be utilized to deliver drugs to the CNS, as for example osmotic disruption [Neuwelt et al., 1980a]. However, generally this is not the case since, for example, exposure to soman is accompanied by seizures  
10 [Petrali et al, 1991].

However, while these methods do provide CNS delivery for some drugs it would be useful to have additional means of delivery. In particular it would be useful to have mechanisms that temporarily and reversibly open the  
15 BBB to allow non-engineered drugs through.

Stress has been shown to affect the permeability of the BBB [Sharma, et al, 1991; Ben-Nathan, et al, 1991]. Further, in mammals, acute stress elicits a rapid, transient increase in released acetylcholine (ACh) with a  
20 corresponding phase of increased neuronal excitability [Imperato, et al, 1991]. There have been some studies showing that the pharmacological blockade of acetylcholine - hydrolyzing enzyme, acetylcholine esterase (AChE) promotes a similar enhancement in  
25 electrical activity in cortical neurons [Ennis and Shipley, 1992].

AChE has three splice variant AChEmRNAs (Figure 1). Alternative splicing controls the generation of proteins with diverse properties from single genes through the  
30 alternate excision of intronic sequences from the nuclear precursors of the relevant mRNAs (Pre-mRNA). It is known to be cell type-, tissue- and/or developmental stage-specific and is considered as the principal mechanism controlling the site(s) and timing of expression and the

properties of the resultant protein products from various genes.

Three alternative AChE-encoding mRNAs have been described in mammals (Figure 1). The dominant brain and muscle AChE (AChE-T) is encoded by an mRNA carrying exon E1 and the invariant coding exons E2, E3, and E4 spliced to alternative exon E6. AChEmRNA bearing exons E1-4 and alternative exon E5 encodes the glycolipid phosphatidylinositol (GPI)-linked form of AChE characteristic of vertebrate erythrocytes (AChE-H). An additional readthrough mRNA (AChE-I4) species (Table 1, SEQ ID No:1) retaining the intronic sequence I4 (SEQ ID No:2; Figure 2) located immediately 3' to exon E4 is found in rodent bone marrow and erythroleukemic cells and in various tumor cells lines of human origin. (The book Human Cholinesterases and Anticholinesterases by Soreq and Zakut (Academic Press, Inc., 1993) provides a summation of the biochemical and biological background as well as the molecular biology of human cholinesterase genes and the proteins. The book in its entirety is incorporated herein by reference.)

It would be useful to facilitate transport through the BBB by using a stress mimicking agent to have a controlled reversible disruption, or opening, of the BBB and/or blood-CSF.

#### SUMMARY OF THE INVENTION

According to the present invention, a pharmaceutical composition for facilitating passage of compounds through the blood-brain barrier comprising the AChE-I4 readthrough (SEQ ID No:1) splice variant or the I4 peptide (SEQ ID No:2) and analogues of each thereof and a pharmaceutically acceptable carrier is disclosed.

Alternatively, the pharmaceutical composition for facilitating passage of compounds through the blood-brain barrier can comprise adrenaline, atropine and dopamine and a combination of dopamine and propanolol and a  
5 pharmaceutically acceptable carrier. Combinations of these agents can also be used.

The composition of the present invention can optionally include the compound to be transported across the BBB. Alternatively, the compound can be co-  
10 administered (simultaneously) with the composition or can be administered at some point during the biologically effective period of the action of the composition. That is the composition facilitates disruption of the BBB, i.e. opens the BBB, for a period depending on the dose  
15 and the compound can be administered during this relevant period.

The present invention provides a method for administering a compound to the CNS of an animal by subjecting the animal to a stress-mimicking agent or  
20 treatment. This agent or treatment facilitates disruption of the blood-brain barrier. During the period that the BBB is opened or disrupted a compound can be administer such that the compound is enabled to passage through the disrupted BBB into the CNS.

25 The method and composition of the present invention therefore provides for delivery to the central nervous system of compounds that are necessary for treatment modalities in any condition affecting the central nervous system where the blood-brain barrier would impede the  
30 delivery of the compound. These conditions can include any disease or pathology of the central nervous system and can include neuropsychiatric disorders. The method and composition of the present invention is an improvement of currently available means of delivery of



compounds to the central nervous system through the blood-brain barrier.

#### DESCRIPTION OF THE DRAWINGS

5 Other advantages of the present invention will be readily appreciated as the same becomes better understood by reference to the following detailed description when considered in connection with the accompanying drawings wherein:

10 FIGURE 1 is a schematic diagram of the three splice variants of AChE.

FIGURE 2 is shows the amino acid sequences of human (H) AChE variants from the end of E4 to the end of the protein in the three variants, E1-4,6 (SEQ ID No:3), E1-5 (SEQ ID No:4), E1-4-I4-E5 (readthrough; SEQ ID No:5).

15 FIGURES 3A-B show that acute stress and anticholinesterases modulate CNS gene expression similarly. Figure 3A are photographs showing RT-PCR analysis, C-fos RT-PCR traces represent mRNA preparations from 10 minute post-treatment, ACHE, synaptophysin and ChAT products represent RNA preparations from 30 minute following either stress or AChE inhibition. One out of 6 reproducible in vivo and in vitro experiments is shown. Figure 3B are extracellular evoked potentials recordings of stratum oriens fibers using glass microelectrodes in the CA1 area before (Control) or 30 minutes following addition of 1  $\mu$ M DFP (Anti-AChE), to the perfusing solution. Note the increased amplitude and duration of evoked extracellular field potentials and the enhanced paired-pulse facilitation. One out of 5 experiments showing AChE inhibition promotes neuronal excitability.

25 FIGURES 4A-D show delayed suppression of the hyperexcitation evoked by AChE inhibition. Graphs at (A) One hour administration of 1 or 10  $\mu$ M carbachol, (B) average and standard deviation values for 6 measurements

30

35

per point of population spikes evoked in response to the noted stimulus intensities in hippocampal slices under control conditions (control, empty circles), or following 1 or 3 hours under continuous perfusion of 10  $\mu$ M physostigmine (filled circles or squares, respectively), (C) graphs show population spike traces from slices under 1 hour control conditions (cont.), following 1 hour under co-exposure to 1  $\mu$ M physostigmine and 1  $\mu$ M atropine (phy+at), or 1 hour after that, when atropine was washed off and under continued exposure to physostigmine. Note the absence of excitation response under atropine and that no suppression took place 1 hour after its removal. Figure 4D are traces of Paired-pulse facilitation enhancement with first and second responses (V1, V2) separated by a 500 msec interval or the difference between such responses (V2-V1) following 50, 100 or 500 msec intervals for hippocampal slices under control conditions or following 1 or 3 hours of perfusion with 1 mM physostigmine. Note the prolonged duration and the intense signals of facilitation responses recorded 1 hour following physostigmine addition to the perfusion medium and the suppression of both these responses after 3 hours of such exposure.

FIGURES 5A-B show that physiological and transcriptional responses both depend on intracellular  $Ca^{++}$  mobilization and  $Na^{+}$  influx. Figure 5A is a graph showing prevention of facilitation enhancement.: Duration of paired-pulse facilitation responses was measured as in Fig. 4C in hippocampal slices under control conditions (empty triangles), 1 hour following the addition of 1  $\mu$ M pyridostigmine to the perfusion medium (full squares) or 1 hour following treatment with both 1  $\mu$ M physostigmine and 1  $\mu$ M BAPTA-AM (full triangles). Note the complete prevention of the physostigmine-induced

prolongation of paired-pulse facilitation under BAPTA-AM. Figure 5B are photographs showing suppression of the transcriptional response: c-fos, ChAT and synaptophysin mRNAs were PCR-amplified as in Fig. 3A from control  
5 slices (cont.) or slices treated for 1 hour with 1 mM pyridostigmine (Pyr) alone, or with pyridostigmine and 1  $\mu$ M of the  $\text{Ca}^{++}$  chelator BAPTA-AM or the  $\text{Na}^{+}$  channel blocker tetrodotoxin (TTX). Note that the anti-cholinesterase-induced changes in c-fos and ChAT mRNA  
10 were both suppressed by either BAPTA-AM or TTX, demonstrating that these transcriptional changes depend both on the increased intracellular  $\text{Ca}^{2+}$  and on  $\text{Na}^{+}$  influx.

FIGURE 6A-B show long term changes in AChE activity  
15 following stress. Figure 6A graph shows specific AChE activities in  $\mu$ mole acetylthiocholine (ATCh) hydrolyzed per hour per mg tissue spectrophotometrically determined in extracts of cortex, cerebellum or hippocampus prepared from animals sacrificed at the noted times after forced  
20 swimming protocol. Presented are percent of control activities for each brain region for 10 out of 20 studied mice. Figure 6B is a photograph showing stress intensifies cortical AChE activity and diversifies its electrophoretic heterogeneity. Cortical protein extracts  
25 were electrophoresed (20  $\mu$ l per lane, 1:10 w/vol) in 7% non-denaturing polyacrylamide gels. Gels were histochemically stained for catalytically active AChE. Note the post-stress increase in activity and the electrophoretic heterogeneity of cortical AChE following  
30 stress. One of 10 experiments.

FIGURE 7A-B shows selective induction of readthrough AChEmRNA following stress and AChE inhibition. Figure 7A are photographs showing kinetic follow-up of RT-PCR: Positions of primer pairs specific for the alternatively  
35 spliced AChEmRNA subtypes are presented on the left.

[Primer pair 1361+/1869- ("E6") detects mRNA encoding the synaptic AChE form; 1361+/175- ("I4/E5") detects both a 549 bp product of readthrough AChEmRNA and a 432 bp product encoding the GPI-lined red blood cell (RBC) form of the enzyme]. Note that both in vivo stress and in vitro AChE inhibition promoted significant increases of the readthrough (I4) but not the synaptic (E6) or erythrocyte (E5) forms of AChEmRNA. The bands displayed in the top right hand panel represent endpoint PCR products from a reaction using a nested readthrough AChEmRNA primer pair (1361+/74-) detected by hybridization with a radiolabelled probe. Figure 7B are photographs showing the result of in situ hybridization: 5  $\mu$ m thick paraffin-embedded cortical slices were incubated with 50-mer 5'-biotinylated, chemically protected complementary RNA probe directed against exon 6 initiated at nt.1869 (left), or intron I4 initiated at position 74 (right), of the mouse AChE gene. Signals were detected using alkaline phosphatase-streptavidin conjugates and Fast Red as a substrate. Shown are cortical layers II-V (upper panels), and magnified pyramidal neurons of cortical layer no. 2 (lower panels). Note that I4 labeling was essentially limited to layers II + V under control conditions, but was intensified and included layer III + IV after exposure to AChE inhibitor (pyridostigmine, 2 mg/kg). Also, the subcellular localization of I4-AChEmRNA shifted from around the nucleus under control conditions to the entire cell bodies and their apical dendrites following AChE inhibition.

FIGURES 8A-D are photographs of mice brains following injection of Evans Blue Dye and (A) control no other treatment, (B) stress induced by forced swimming, (C) adrenaline and (D) atropine.

FIGURE 9A-F demonstrates that stress intensifies AChE inhibition by pyridostigmine due to increased brain penetration. A: AChE inhibition in brain homogenates. Acetylthiocholine hydrolysis was measured following addition of increasing concentrations of pyridostigmine (filled squares) or physostigmine (empty circles) to brain homogenates from control animals. Presented are percent remaining activities as compared with those of brain homogenates with no added drug. B: Inhibiting brain AChE activity by drug injection. Percent of normal specific cortical AChE activity was measured in brain homogenates prepared from non-stressed animals sacrificed 10 minutes following injection of the noted doses of physostigmine (n=9) or pyridostigmine (n=11). Presented are percent remaining activities as compared with those of brain homogenates from non-stressed, 0.9% NaCl injected animals (n=12). C: Pyridostigmine inhibition of brain AChE following stress. Swim forced test was followed 10 minutes later by injection of either 0.1 mg/kg pyridostigmine (n=8), or physostigmine (n=5). AChE activity measurements were as under B. Presented are percent remaining activities as compared with those of brain homogenates from similarly stressed, 0.9% NaCl injected animals (n=6). D: BBB permeability following stress. Shown are representative brains dissected from anaesthetized animals, 10 minutes following intracardial injection of Evan's-blue. Control: non-stressed animal, stress: 10 minutes following stress session. E: Plasmid DNA penetration to the brain under stress. Control and stressed animals were injected i.p. with CMVACHE [Ben Aziz-Aloya, et al, 1993] plasmid. Proteinase K-treated brain homogenates were subjected to PCR amplification using a set of CMV-promoter forward primer and an ACHE reverse primer. PCR product samples were withdrawn every third cycle, which allows for 8-fold increases between

samples. CMVACHE DNA was detected starting from cycle 21 in the brain of 4 out of 4 stressed animals. The PCR products from brain of control animals were considerably weaker and appeared only on cycle 24, indicating at least 8-fold less plasmid DNA in control brains as compared to stressed ones. In 2 out of 5 control animals no PCR product was detected. F: Kinetics of brain c-fos cDNA accumulation during RT-PCR amplification. Total RNA from mouse hippocampus was extracted using RNAClean (AGS, Heidelberg, Germany), its integrity verified by gel electrophoresis (evaluation of 2.0 ratio between 28 S and 18 S ribosomal RNA) and its quantity and purity from protein contamination evaluated by a A260/A280 ratio of 1.8-2.0. c-fos cDNA was amplified following reverse transcription of equal amounts of total RNA samples from the brain of control or stressed animals. Kinetic follow-up of product accumulation was carried out as under E. The earlier appearance of amplified c-fos cDNA, 20 minutes following stress session as compared to control, indicates a significant increase in the amount of c-fos mRNA under stress.

FIGURE 10A-B: Pyridostigmine enhances neuronal excitability and increases oncogene mRNA levels. A: The kinetics of brain c-fos and AchE mRNA accumulation during RT-PCR amplification. RNA was extracted and reverse transcribed as under Fig. 9. The earlier appearance of the amplified PCR product 20 minutes following injection of 2 mg/kg pyridostigmine (+) as compared to 0.9% NaCl (-) indicates an increase in the amount of c-fos (upper panel) and AchE mRNA (lower panel) under pyridostigmine exposure. B: Extracellular evoked potentials. Cortico-hippocampal slices (400  $\mu$ m thick) were cut using a vibratome (Vibroslice, Campden Instruments, Loughborough, UK.), and were placed in a humidified holding chamber, continuously perfused with oxygenated (95% O<sub>2</sub>, 5% CO<sub>2</sub>)

artificial cerebrospinal fluid (aCSF) [Blick et al, 1994]. Schaffer collateral fibers were stimulated with a bipolar tungsten stimulating electrode and extracellular evoked potentials were recorded in the cell-body layer of the CA1 area of the hippocampus. Single response to supramaximal stimulus intensity (1.5 times stimulus the intensity of which caused maximal response) is drawn before (-) and 30 minutes following (+) addition of pyridostigmine (1 mM) to the perfusing solution.

FIGURE 11A-D are graphs showing pyridostigmine effects in humans during peace and war and in non-stressed and stressed rodents. Left panels (A-B): Results of a double blind, placebo controlled study (dashed bars, "peace"). Pyridostigmine (n=18) or placebo (n=17) were administered to healthy young male volunteers. Symptoms were reported at the end of the study. Presented are ranges (%) of soldiers reporting pyridostigmine-induced symptoms related to CNS (A) or PNS (B). During the Gulf War 213 male soldiers aged 18-22 years were questioned, 24 hours after initiation of pyridostigmine treatment (filled bars). Right panels (rodents, C-D): summary of measured brain AChE inhibition (C) and serum BuChE inhibition in mice (D) 10 minutes following injection of 0.1 mg/kg pyridostigmine in non-stressed (control, n=4), and stressed (n=5) mice. Percent inhibition (standard deviation was calculated in comparison to the average activity calculated in non-injected, not-stressed (n=12) and stressed (n=6) animals.

FIGURE 12A-F are graphs showing the CT signal for control population wherein (A) is neck soft tissue, (B) posterior fossa, (C) pons, (D) thalamus, (E) white matter and (F) cortex frontal lobe.

FIGURE 13 is a graph of control versus neurological patients showing the percent of enhanced contrast between

the two groups wherein p.f. is posterior fossa, thal is thalamus and wm is white matter.

FIGURE 14A-B shows the diffusion of horseradish peroxidase into brains following disruption of the BBB wherein (A) is a diagrammatic representation of the brain and areas evaluated for dye concentration and (B) are photomicrographs of this regions in control non-stressed (cont.) and stress animals.

FIGURE 15 is a graph showing the response to stress mimicking adrenergic manipulation of the BBB to pyridostigmine wherein --O-- is pyridostigmine only, --■-- is pyridostigmine plus dopamine (DA), --▲-- is pyridostigmine plus propanolol and --●-- is pyridostigmine plus DA and propanolol.

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a pharmaceutical composition with agents for facilitating passage of compounds through the blood-brain barrier (BBB) into the central nervous system (CNS). As used herein the term BBB also encompasses the blood-CSF barrier. The composition comprises an effective amount of the AChE-I4 readthrough (SEQ ID No:1) splice variant protein and a pharmaceutically acceptable carrier. Alternatively the composition comprises an effective amount of the I4 peptide (SEQ ID No:2) and a pharmaceutically acceptable carrier. The composition can also comprise an effective amount of at least one of dopamine (DA), atropine and/or adrenalin and a pharmaceutically acceptable carrier. Further, the agent can be a combination of an  $\alpha$  adrenergic agonist and  $\beta$  adrenergic antagonist referred to herein after as an adrenergic combination agent such as dopamine and propanolol. Combinations of these agents can be used. These compositions facilitate a



reversible disruption (opening) of the BBB allowing transport of compounds through the BBB.

5 Analogues with the same biological activity as SEQ ID Nos:1-2 can be used in the pharmaceutical composition of the present invention. The term analogue as used herein is defined as a variant amino acid sequence alteration, with some differences in their amino acid sequences as compared to the native sequence of SEQ ID Nos:1-2. The amino acid sequence of an analog may differ  
10 from that of the SEQ ID Nos:1-2 when at least one residue is deleted, inserted or substituted, but the protein and/or peptide retains its biological activity with respect to the present invention.

15 The amount administered is determined as shown in the examples herein, generally by dye exclusion tests, calibrated to show the amount necessary to open or disrupt the BBB and the duration of the disruption. CT scans in particular as shown in Example 5 are particularly useful in establishing the amount  
20 administered as is the method disclosed in Example 6. These amounts are determined on a species basis and are administered and dosed in accordance with good medical practice, taking into account the clinical condition of the individual patient, the site and method of  
25 administration, scheduling of administration, patient age, sex, body weight and other factors known to medical practitioners. The pharmaceutically "effective amount" for purposes herein is thus determined by such considerations as are known in the art. The amount must  
30 be effective to achieve a reversible disruption of the BBB. In general the amounts used in Examples 2 and 6 can be used with the appropriate conversion to human dosages as is known in the art.

35 The composition of the present invention can optionally include the compound to be transported across

the BBB. Alternatively, the compound can be co-administered (simultaneously) with the composition or can be administered at some point during the biologically effective period of the action of the composition. That  
5 is the composition facilitates disruption of the BBB, i.e. opens the BBB, for a period depending on the dose and the compound can be administered during this relevant period.

The compounds are used for diagnostic or treatment  
10 modalities in any condition affecting the central nervous system where the blood-brain barrier would impede the delivery of the compound. For example, the composition of the present invention can be used to deliver contrast  
agents (dyes) that are needed for imaging of the CNS.  
15 These conditions can include any disease or pathology. They can include, but are not limited to, infections, neurochemical disorders, brain tumors and gliomas, demyelination, other neuropathies, encephalopathies, coma, ischemia, hypoxia, epilepsy, dementias, cognitive  
20 disorders, neuropsychiatric disorders (including depression, anxiety, schizophrenia and the like) as well as genetic disorders. The compounds to be administered can range from antibiotics to chemotherapeutic drugs to vectors to be used for gene therapy. The compounds can  
25 include agents that can be used to block the effects of abused drugs. These compounds are administered and dosed as is known in the art for these compounds in accordance with good medical practice, taking into account the clinical condition of the individual patient, the site  
30 and method of administration, scheduling of administration, patient age, sex, body weight and other factors known to medical practitioners. The pharmaceutically "effective amount" for purposes herein is thus determined by such considerations as are known in  
35 the art. The compound can be administered in various

ways which are selected to deliver the compound to the BBB at the appropriate time when the barrier has been disrupted or opened to facilitate transport through the BBB into the CNS. The patient being treated is a warm-blooded animal and, in particular, mammals including man. It is noted that humans are treated generally longer than the mice or other experimental animals exemplified herein which treatment has a length proportional to the length of the disease process and drug effectiveness and body size and metabolism.

The present invention provides a pharmaceutical composition for facilitated administration of a compound or drug through the blood-brain barrier. The compound or drug is given in combination with an inducing means for mimicking stress and a pharmaceutically acceptable carrier. The inducing means can include either administering a stress-mimicking agent or applying a stress-mimicking inducing treatment.

A stress-mimicking inducing treatment is hypnosis [Solomon et al, 1992; Spiegel, 1992; Putnam, 1992]. The use of hypnosis allows the recalling of stressful events in a controlled environment. The recall of the stressful events generates the release of AChE-I4 in the brain thereby generating *in situ* a disruption of the BBB. The timing of the administration of the compound is timed to coincide with the window of time of relived stress.

Stress-mimicking agents such as dopamine, adrenaline and/or atropine can be used as shown herein in the examples. For example, adrenaline is released in stress, therefore its administration mimics a stress. Stress-mimicking agents such as AChE-I4 (SEQ ID No:1) or I4 peptide (SEQ ID No:2) can also be used since they are also released in response to stress and therefore their administration mimics a stress. An adrenergic combination agent consisting of an  $\alpha$  adrenergic agonist

and  $\beta$  adrenergic antagonist can also be used such as dopamine and propranolol respectively. Combinations of these stress mimicking agents can also be used.

5 The amount administered is determined as shown in the examples herein, generally by dye exclusion tests, calibrated to show the amount necessary to open or disrupt the BBB and the duration of the disruption. CT scans can be used for the calibration as can the method set forth in Example 6. These amounts are determined on  
10 a species basis and are administered and dosed in accordance with good medical practice, taking into account the clinical condition of the individual patient, the site and method of administration, scheduling of administration, patient age, sex, body weight and other  
15 factors known to medical practitioners. The pharmaceutically "effective amount" for purposes herein is thus determined by such considerations as are known in the art. The amount must be effective to achieve a reversible disruption of the BBB.

20 The present invention provides a method for administering a compound to the CNS of an animal by subjecting the animal to a stress-mimicking agent or treatment. This agent or treatment facilitates disruption of the blood-brain barrier. During the period  
25 that the BBB is opened or disrupted a compound can be administer such that the compound is enabled to passage through the disrupted BBB into the CNS.

A stress-inducing treatment is hypnosis [Solomon et al, 1992; Spiegel, 1992; Putnam, 1992] as described  
30 herein above. Stress inducing agents such as adrenaline, atropine, dopamine and adrenergic combination agents can be used as shown herein in the examples. Stress mimicking agents such as ACHE-I4 (SEQ ID No:1) or I4 peptide (SEQ ID No:2) can be used. These agents can be  
35 used in combination.

The administration of the compound can be simultaneous with subjecting the patient to a means of inducing stress (treatments and/or agents). Alternatively, the compound can be administered during  
5 the time period when the BBB is reversibly open.

In Example 1, BBB permeability in response to stress is shown in mice and humans utilizing pyridostigmine brain penetration studies. Pyridostigmine, a carbamate acetylcholinesterase (AChE) inhibitor, is routinely  
10 employed in the treatment of the autoimmune disease myasthenia gravis [Taylor, 1990]. Pyridostigmine is also recommended by most western armies for use as pretreatment under threat of chemical warfare, because of its protective effect against organophosphate poisoning  
15 [Deyi et al, 1981; Diruhumber et al, 1979]. Due to this drug's quaternary ammonium group, which prevents its penetration through the blood-brain-barrier (BBB), the symptoms associated with its routine use primarily reflect perturbations in peripheral nervous system  
20 functions [Taylor et al, 1990; Borland et al, 1985]. Unexpectedly, under similar regimen, pyridostigmine administration during the Gulf War resulted in an >3 fold increase in the frequency of reported central nervous system symptoms [Sharabi et al, 1991]. This was not due  
25 to enhanced absorption (or decreased elimination) of the drug because the inhibition efficacy of serum butyrylcholinesterase was not modified [Sharabi et al, 1991].

In Example 2 BBB permeability to Evans Blue dye following stress or the administration of adrenaline or atropine is shown. These results show that adrenaline or atropine can, at physiologically meaningful doses, provide increased permeability of the BBB. This study is further explored in Example 4 where the BBB permeability  
30 to Horseradish peroxidase is studied and more detailed  
35

neuroanatomical detail is determined. In Example 6, adrenergic manipulation of the BBB permeability is disclosed, showing that simultaneous activation of  $\alpha$  adrenergic receptors together with blockade of  $\beta$  adrenergic receptors effects a synergistic effect on BBB permeability/disruption.

In Example 3 pronounced reductions in choline acetyltransferase and vesicular acetylcholine transporter mRNAs accompanied prolonged increases in a rare acetylcholinesterase variant (readthrough AchE-I4) in acutely stressed mice and in anticholinesterase-treated mice and hippocampal brain slices. These calcium-dependent modulations in gene expression coincided with transient enhancement and delayed depression phases of neuronal excitability, both mediated by acute cholinergic stimulation. Our findings implicate concerted cholinergic feedback mechanisms in parallel long-term responses to stress and exposure to anticholinesterases.

In Example 5 Computerized Tomography (CT) was used to measure the amount of disruption of the BBB and to correlate this disruption with CSF protein content and cholinergic activity.

The above discussion provides a factual basis for the use of stress-mimicking compounds or treatments to facilitate disruption of the BBB to delivery compounds to the CNS. The methods used with and the utility of the present invention can be shown by the following non-limiting examples and accompanying figures.

30

## EXAMPLES

### GENERAL METHODS:

General methods in molecular biology: Standard molecular biology techniques known in the art and not specifically described were generally followed as in Sambrook et al., *Molecular Cloning: A Laboratory Manual*,

35

Cold Springs Harbor Laboratory, New York (1989, 1992), and in Ausubel et al., *Current Protocols in Molecular Biology*, John Wiley and Sons, Baltimore, Maryland (1989). Polymerase chain reaction (PCR) was carried out generally as in *PCR Protocols: A Guide To Methods And Applications*, Academic Press, San Diego, CA (1990). In-situ (In-cell) PCR in combination with Flow Cytometry can be used for detection of cells containing specific DNA and mRNA sequences (Testoni et al, 1996, Blood 87:3822.)

Reactions and manipulations involving other nucleic acid techniques, unless stated otherwise, were performed as generally described in Sambrook et al., 1989, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, and methodology as set forth in United States patents 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057 and incorporated herein by reference.

**Stress Induction:** Stress was induced in adult FVB/N mice by 2 x 4 minute forced swim with a 4 minute rest interval in a 60x60 cm water bath at about 21°C, adapted from Melia et al, [1994]. Ten minutes following stress-induction animals were injected i.p. with 0.9% NaCl (control), pyridostigmine (Research Biochemical International, Natick, MA) or physostigmine (Sigma, St Louis, MI ) at the indicated doses. Animals were decapitated 10 minutes following injection, trunk blood was collected [Melia et al, 1994], and cerebral cortex was quickly dissected and homogenized in solution D (10 mM Tris-HCl, pH 7.4, 1M NaCl, 1% Triton-X100, 1 mM EDTA, 1:10 weight/volume) [Neville et al, 1990]

**AChE activity measurements:** Acetylthiocholine (ATCh) hydrolysis levels were determined spectrophotometrically in nmol ATCh per minute per mg brain protein, as previously described [Seidman et al, 1995]. BuChE activity in serum was measured using Butyrylthiocholine (BTCh) as substrate. In both cases, selective inhibitors

were employed to suppress non-specific hydrolysis [Neville et al, 1990].

**Determination of Blood-Brain-Barrier permeability:**

Evan's Blue: Anaesthetized animals (Nembutal, 60 mg/kg),  
5 were injected intracardially with 0.1 ml of 2% of the  
albumin-binding dye Evan's-blue in 0.9% NaCl. Following  
perfusion with 0.9% NaCl, brains were removed,  
homogenized and dye concentration determined  
spectrophotometrically [Uyama et al, 1988]. Plasmid DNA:  
10 100 ug of plasmid CMVACHE DNA (ca. 6 Kb) in 0.1 ml of  
0.9% of NaCl was injected i.p. into control or stressed  
animals. Animals were sacrificed 20 minutes following  
injection, trunk blood and brain were collected and  
plasmid DNA detected by kinetic follow-up of PCR  
15 amplification in tissue homogenates treated with  
proteinase K (100 (g/ml, overnight incubation, 65°C).

RT-PCR: Brain c-fos cDNA was amplified by RT-PCR  
using as primers 1604(+):

5'TCTTATTCGTTCCCTTCGGATTCTCCGTT3' (SEQ ID No;6) and  
20 2306(-): 5'TCTTATTCGTTCCCTTCGGATTCTCCGTT3' (SEQ ID  
No:7). Brain AChE cDNA was amplified using as primers  
375(+): 5'AGACTGCCTGTATCTTAATGTGTGGACACC 3' (SEQ ID No:8)  
and1160(-): 5' CGGCTGATGAGAGATTCATTGTCTTTGCTG 3' (SEQ ID  
No:9). Numbers. denote nucleotide positions in the  
25 Genbank c-fos sequence (accession no. V00727), or in the  
mouse AChE cDNA sequence [Rachinsky et al, 1990]  
respectively. Ten ml of each reaction mixture, were  
removed every third cycle from 18 to 39, electrophoresed  
and stained with ethidium bromide [Seidman et al, 1995].

30 **Electrophysiological Recordings:** Extracellular  
potentials were recorded in hippocampal slices maintained  
in vitro [Friedman and Gutnick, 1989]. Schaffer  
collateral fibers were stimulated with a bipolar tungsten  
stimulating electrode. Recording glass microelectrodes  
35 were located in the CA1 area.



## EXAMPLE 1

In this Example a forced swim protocol, shown previously to induce stress [Melia et al, 1994], gives an increase in BBB permeability and reduces by >100 fold the pyridostigmine dose required to inhibit mouse brain AChE activity by 50%. Under these conditions, peripherally administered pyridostigmine increased the brain levels of c-fos oncogene and AChE mRNAs. Moreover, in-vitro exposure to pyridostigmine increased both electrical excitability and c-fos mRNA levels in brain slices, demonstrated that the observed changes could be directly induced by pyridostigmine. These findings demonstrate that peripherally acting drugs administered under stress may reach the brain and affect centrally controlled functions.

Pyridostigmine and physostigmine displayed similar efficacy in inhibiting AChE activity when added to brain homogenates (Fig. 9A). Also, they were similarly effective in reducing serum butyrylcholinesterase (BuChE) activity when injected intraperitoneally (i.p.) into non-stressed mice (16.7 +/- 6.9% and 22.6 +/- 5.4% reduction from normal levels respectively, 10 minutes following injection of 0.1 mg/kg pyridostigmine or physostigmine into 3 animals in each group). However, brain AChE activity in homogenates prepared from non-stressed mice was considerably less inhibited by the injected pyridostigmine than by physostigmine (Fig. 9B). Thus, pyridostigmine doses previously proven to be protective against organophosphates (0.1-0.5 mg/kg, 15-30% inhibition of serum BuChE activity) [Deyi et al, 1981; Diruhumber et al, 1979] did not reduce brain AChE levels, whereas similar doses of physostigmine inhibited more than 50% of brain AChE activity (Fig. 9B).

In contrast, AChE activity measured in homogenates from the cerebral cortex of drug-injected stressed mice,

was reduced by 0.1 mg/kg of either pyridostigmine or physostigmine to less than 50% of normal level (Fig. 9C). The stress treatment therefore reduced the pyridostigmine dose required to inhibit 50% of brain AChE from 1.50 to  
5 0.01 mg/kg. This coincided with a >10-fold increase in brain penetration of either the albumin-binding dye Evans-blue (Fig. 9D) or CMV AChE plasmid DNA [Ben Aziz-Aloya et al 1993] (Fig. 9E) under stress.

As the pyridostigmine doses that inhibited cortical  
10 AChE activity in non-stressed mice (>1mg/kg) were reported to perturb CNS functions in primates [Blick et al, 1994], its effect was examined on mRNA levels of the c-fos oncogene, an indirect marker for enhanced neuronal excitability [Melia et al, 1994], by reverse  
15 transcription followed by PCR amplification (RT-PCR). Earlier appearance of PCR product, reflecting over 100-fold increase in brain c-fos mRNA level was evident in stressed as compared with control animals (Fig. 9F), in line with previous reports [Melia et al, 1994]. A  
20 similar increase in c-fos mRNA was observed in non-stressed animals as soon as 10 minutes following i.p. injection of 2 mg/kg pyridostigmine (95% inhibition of cortical AChE) (Fig. 10A, upper panel).

To explore the direct effect of pyridostigmine on  
25 cholinergic brain circuits, electrophysiological and molecular neurobiology analyses were undertaken on in-vitro maintained brain slices [Friedman and Gutnick, 1989]. Direct application of 1 mM pyridostigmine to hippocampal slices reduced AChE activity within 30  
30 minutes with similar efficacy to that observed in vivo at a dose of 2 mg/kg (data not shown) and induced a parallel 100-fold increase in c-fos mRNA levels. Control tests with primers for synaptophysin mRNA revealed no change either in vivo or in brain slices, demonstrating the  
35 selectivity of the above responses (data not shown).

Moreover, the earlier appearance of AChE mRNA product under pyridostigmine administration (Fig. 10A, lower panel), reflects an association between c-fos levels and the transcriptional control of key cholinergic proteins. Electrophysiological recordings in such slices revealed a pyridostigmine-induced increase in the amplitude and rate of rise of evoked population spikes in the CA1 area of the hippocampus, in response to stimulation of the Schaffer Collaterals (Fig. 10B). This enhancement in summated neuronal activity demonstrated directly the increased excitability of the local circuit following pyridostigmine application.

Double-blind human studies testing pyridostigmine effects on 35 young healthy volunteers ("peace time", [Glickson et al, 1991] and additional data, not reported previously) as compared to those observed in 213 treated soldiers during the Gulf War [extension of Sharabi et al, 1991] resemble the current rodent data in this Example. In both human studies each individual was asked to report on a yes/no questionnaire regarding symptoms related to the drug. During peace time, in agreement with previous reports [Taylor, 1990; Borland et al, 1985] documented symptoms were mainly related to peripheral nervous system (PNS) functions (symptoms included: abdominal pain, diarrhea, frequent urination, increased salivation, rhinorrhea and excess sweating) with an average of 18.8%, (range: 5.5-38.9%), while only 8.3% (range: 0-16.6%) of participants reported symptoms related to CNS functions (headaches, insomnia, drowsiness, nervousness, difficulties in focusing attention and impaired calculation capacities) (Fig.11 dashed bars).

In contrast, extension of the reported study performed during the Gulf War [Sharabi et al, 1991], revealed that 23.6% (range: 6.2-53.4%) of the 213 soldiers reported on CNS symptoms while only 11.4%

(range: 6.1-20.4%) reported PNS symptoms (Fig. 11, filled bars). In parallel, in control mice injected with 0.1 mg/kg pyridostigmine, serum BuChE activity was inhibited similarly to that measured in humans at peace time  
5 (18.8(3.5% in humans and 20.4(5.5% in mice). Under these conditions, no inhibition of mouse brain AChE was measured (see also Fig. 9B). Injection of similar doses of pyridostigmine to stressed mice caused a significant inhibition of mouse brain AChE, with a tendency toward  
10 limitation of BuChE inhibition (Fig. 11). Thus, PNS effects were relatively suppressed and CNS effects-enhanced, probably due to either the restraint stress in mice or the psychological stress associated with war in humans.

15 These findings demonstrate significant correlation between stress and pyridostigmine-induced CNS effects. These data confirm previously accepted idea that treating non-stressed mice with prophylactic doses of pyridostigmine does not inhibit CNS AChE, corresponding  
20 to unaffected CNS functions in non-stressed primates [Blick et al, 1994] or humans at peace time [Borland et al, 1985]. Yet, similar treatment under stress conditions (in mice) was associated with increased brain penetration, significant inhibition of brain AChE  
25 activity, increased neuronal excitability and oncogene activation. This increase in c-fos mRNA levels may explain the induction of AChE transcription by the presence of a c-fos binding site in the mammalian AChE promoter [Ben Aziz-Aloya et al, 1993; Ekstrom et al,  
30 1993].

Since central cholinergic neurotransmission systems are normally involved in stress responses [McEwan and Sapolsky, 1995] access of pyridostigmine to the brain can be expected to add yet more "stress like" symptoms to  
35 those associated with the war situation. . That some of

the associated stress effects seen in this Example parallel those reported during the Gulf War further strengthens these observations.

5

## EXAMPLE 2

As shown in Example 1, stress increased permeability of the blood-brain barrier (BBB). This work suggested a link between alteration in BBB permeability and  
10 activation of central adrenergic pathways. To test this the BBB permeability to Evans Blue dye was tested in FVB/N mice following stress (forced swim) or administration of adrenaline or atropine.

Control FVB/N mice were injected with 0.1 ml 4% Evans Blue dye (Catalog #E2129, Sigma Chemical Co., St. Louis, MO). Mice were also injected similarly 10 minutes  
15 after stress-inducing forced swimming [Melia et al, 1994] or an ip injection of adrenaline or atropine (30 mg/kg). After 10 minutes, the mice were sacrificed and brain removed. 200  $\mu$ m sections were prepared from fresh  
20 tissue, mounted on slides, and examined. Animals were anesthetized with Nembutal during the injection procedures.

Examination of the tissue demonstrated enhanced BBB permeability to Evans Blue following stress and  
25 administration of either adrenaline or atropine (Figure 8). In all mice examined, dye was observed within brain capillaries. However, only in the stress-treated or drug-treated animals could dye be observed to diffusely  
30 stain brain tissues. At the administered doses and time course examined, atropine appeared at least as effective as stress in opening the BBB while adrenaline was somewhat less effective.

35

## EXAMPLE 3

Acute traumatic stress may lead to post-traumatic stress disorder (PTSD), a clinical syndrome characterized by delayed neuropsychiatric symptoms such as depression, irritability, restlessness, and impaired cognitive performance [Sapolsky, 1996; Bremner et al, 1995; Gurvitis et al, 1993]. While it is generally assumed that PTSD is associated with sustained modifications in central cholinergic functions, it is not yet known how a single stressful event might mediate long-term neuronal plasticity. In mammals, acute stress elicits a rapid, transient increase in released acetylcholine (ACh) with a corresponding phase of increased neuronal excitability [Imperato et al, 1991]. Pharmacological blockade of the ACh-hydrolyzing enzyme acetylcholinesterase (AChE) promotes a similar enhancement in electrical activity in cortical neurons [Ennis and Shipley, 1992], presumably by increasing available neurotransmitter. The cholinergic activation associated with both traumatic stress and cholinesterase inhibition, together with the observation that even a single exposure to AChE inhibitors may induce psychopathologies strikingly reminiscent of PTSD [Rosenstock et al, 1991], suggests that the long-term effects of stress and anticholinesterase intoxication may derive from a common pathway initiated by a burst of intense cholinergic activity.

To explore the mechanism(s) by which acute cholinergic stimulation might promote long-term changes in cholinergic neurotransmission, in this Example transcriptional and post-transcriptional regulation of genes encoding key cholinergic proteins following either acute stress (forced swimming) or exposure to anti-cholinesterase drugs and correlated them with electrophysiological activity in the hippocampus were studied.

RT-PCR analysis: Total RNA was extracted from cortex of FVB/N mice sacrificed 80 minutes following 2 x 4 minutes of forced swimming (stress) or from cortico-hippocampal slices treated with 1  $\mu$ M DFP (diisopropylfluorophosphate an anti-AChE) for 30 minutes. Care of animals and the conduction of these experiments were in accordance with institutional guidelines. Kinetic follow-up of RT-PCR was performed, using the 375+/1160-primer pair which amplifies the region common to all AChEmRNA subtypes and primer pairs specific for ChAT, c-fos, and synaptophysin mRNAs [Friedman et al 1996; Layer et al, 1995; Beeri et al, 1995]. PCR products were sampled every third cycle, electrophoresed and stained with ethidium bromide. Products from 6 consecutive samples are presented for each experimental group and primer pair in Figure 3. The first PCR cycle when a product can be detected reflects the initial amount of the corresponding mRNA in the tested sample. A difference of three in the first cycle of appearance of product reflects approximate 8-fold difference in the initial concentration of each specific RNA [Friedman et al, 1989]. Control: RNA from non-treated animals, which revealed similar patterns to non-treated slices (not shown). C-fos RT-PCR traces represent mRNA preparations from 10 minute post-treatment; AChE, synaptophysin and ChAT products represent RNA preparations from 30 minute following either stress or AChE inhibition.

Stratum oriens fibers were stimulated in hippocampal slices maintained in vitro with a bipolar tungsten electrode as shown in Figure 3B and the extracellular evoked potentials recorded using glass microelectrodes in the CA1 area before (Control) or 30 minutes following addition of 1M DFP (Anti-AChE), to the perfusing solution.

Changes in population spikes are shown to be cholinergic (Figure 4A): One hour administration of 1 or 10  $\mu$ M carbachol (CCh) increased the amplitude of population spikes (mv) as dependent on excitation intensity [I(mA)] in a dose-dependent manner, suggesting involvement of ACh in this response. Delayed repression of increased population spikes is shown in Figure 4B and are average and standard deviation values for 6 measurements per point of population spikes evoked in response to the noted stimulus intensities in hippocampal slices under control conditions (control, empty circles), or following 1 or 3 hours under continuous perfusion of 10  $\mu$ M physostigmine (filled circles or squares, respectively). Increased population spikes and their suppression are both mediated by muscarinic synapses as shown in Figure 4C1 and C2. Drawn are population spike traces from slices under 1 hour control conditions (cont.), following 1 hour under co-exposure to 1  $\mu$ M physostigmine and 1  $\mu$ M atropine (phy+at), or 1 hour after that, when atropine was washed off and under continued exposure to physostigmine. Note the absence of excitation response under atropine and that no suppression took place 1 hour after its removal.

In Figure 4D Paired-pulse facilitation enhancement is shown to be transient: Drawn are first and second responses (V1, V2) separated by a 500 msec interval or the difference between such responses (V2-V1) following 50, 100 or 500 msec intervals for hippocampal slices under control conditions or following 1 or 3 hours of perfusion with 1 mM physostigmine. Note the prolonged duration and the intense signals of facilitation responses recorded 1 hour following physostigmine addition to the perfusion medium and the suppression of both these responses after 3 hours of such exposure.



Sagittal brain slices were maintained under the above detailed conditions, except that KCl concentration was modified to 10 mM. RNA extraction followed by RT-PCR amplification demonstrated stable maintenance of mRNA levels for the key genes detailed in this report for as long as 12 hours.

Physiological and transcriptional responses measuring intracellular  $\text{Ca}^{++}$  mobilization and  $\text{Na}^{+}$  influx were performed (Figure 5). Prevention of facilitation enhancement was measured by duration of paired-pulse facilitation responses in hippocampal slices under control conditions (empty triangles), 1 hour following the addition of 1  $\mu\text{M}$  pyridostigmine to the perfusion medium (full squares) or 1 hour following treatment with both 1  $\mu\text{M}$  physostigmine and 1  $\mu\text{M}$  BAPTA-AM (full triangles). Note the complete prevention of the physostigmine-induced prolongation of paired-pulse facilitation under BAPTA-AM. Suppression of the transcriptional response was shown with c-fos, ChAT and synaptophysin. mRNAs were PCR-amplified from control slices (cont.) or slices treated for 1 hour with 1 mM pyridostigmine (Pyr) alone, or with pyridostigmine and 1  $\mu\text{M}$  of the  $\text{Ca}^{++}$  chelator BAPTA-AM or the  $\text{Na}^{+}$  channel blocker tetrodotoxin (TTX). The anti-cholinesterase-induced changes in c-fos and ChAT mRNA were both suppressed by either BAPTA-AM or TTX, demonstrating that these transcriptional changes depend both on the increased intracellular  $\text{Ca}^{2+}$  and on  $\text{Na}^{+}$  influx.

Long term changes in AChE activity following stress were measured. Specific AChE activities in (mole acetylthiocholine (ATCh) hydrolyzed per hour per mg tissue were spectrophotometrically determined [Ben Aziz-Aloya et al, 1993) in extracts of cortex, cerebellum or hippocampus prepared from animals sacrificed at the noted times after forced swimming protocol [Melia et al, 1994].

Percent of control activities for each brain region for 10 out of 20 studied mice are shown (Figure 6) and show stress intensifies cortical AChE activity and diversifies its electrophoretic heterogeneity. Cortical protein  
5 extracts were electrophoresed (20 ul per lane, 1:10 w/vol) in 7% non-denaturing polyacrylamide gels. Gels were histochemically stained for catalytically active AChE. Recombinant human E6-AChE (rE6) and I4 AChE (rI4) produced in *Xenopus* oocytes [Ghosh et al, 1994] (1:5  
10 oocyte/lane) served as known correlates. The post-stress activity and the electrophoretic heterogeneity of cortical AChE increased following stress.

Selective induction of readthrough AChEmRNA following stress and AChE inhibition were measured using  
15 kinetic follow-up of RT-PCR. The positions of primer pairs specific for the alternatively spliced AChEmRNA subtypes are presented on the left of the Figure 7. [Primer pair 1361+/1869- ("E6") detects mRNA encoding the synaptic AChE form; 1361+/175- ("I4/E5") detects both a  
20 549 bp product of readthrough AChEmRNA and a 432 bp product encoding the GPI-lined red blood cell (RBC) form of the enzyme]. Both in vivo stress (forced swimming) and in vitro AChE inhibition promoted significant increases of the readthrough (I4) but not the synaptic  
25 (E6) or erythrocyte (E5) forms of AChEmRNA. The bands displayed in the top right hand panel of Figure 7 represent endpoint PCR products from a reaction using a nested readthrough AChEmRNA primer pair (1361+/74-) detected by hybridization with a radiolabelled probe  
30 [Lewis et al, 1967]. In situ hybridization was undertaken using 5 uM thick paraffin-embedded cortical slices were incubated with 50-mer 5'-biotinylated, chemically protected complementary RNA probe [Melia et al 1994] directed against exon 6 initiated at nt.1869 or  
35 intron I4 initiated at position 74, of the mouse AChE

gene (accession no. x56518). Signals were detected using alkaline phosphatase-streptavidin conjugates and Fast Red as a substrate. Figure 7B shows cortical layers II-V (upper panels), and magnified pyramidal neurons of cortical layer no. 2 (lower panels). I4 labeling was essentially limited to layers II + V under control conditions, but was intensified and included layer III + IV after exposure to AChE inhibitor (pyridostigmine, 2 mg/kg). Also, the subcellular localization of I4-AChEmRNA shifted from around the nucleus under control conditions to the entire cell bodies and their apical dendrites following AChE inhibition. Stress treatment induced similar changes (not shown).

#### DISCUSSION

As in Example 1, adult FVB/N mice subjected to either a forced swimming stress-inducing protocol [Melia, et al, 1994] or injected with an AChE inhibitor display dramatic increases in brain mRNAs encoding the early immediate transcription factor c-fos. In vitro, cortico-hippocampal brain slices exposed to various AChE inhibitors displayed enhanced neuronal excitability and similar rapid increases in cortical c-fos gene expression (Figure 3A). The presence of c-fos binding sites in the promoters of several genes encoding key cholinergic elements, including AChE [Ben Aziz-Aloya et al, 1993], the acetylcholine synthesizing enzyme choline acetyltransferase (ChAT) [Bausero et al, 1993] and the vesicular acetylcholine transporter (VACHT) [Eiden and Erickson, 1997] suggested that acute stress and/or anti-cholinesterase exposure, via cholinergic stimulation and elevated c-fos, might activate regulatory pathway(s) leading to longterm changes in the expression of proteins mediating brain cholinergic neurotransmission.

To examine changes in CNS gene expression associated with acute stress or cholinesterase inhibition, a semi-

quantitative RT-PCR [Karpel et al, 1994] was performed on cortical RNA extracted from mice sacrificed 80 minutes following forced swimming or cortico-hippocampal slices [Friedman and Gutnick, 1989] harvested following 30  
5 minute exposure to DFP. These analyses revealed pronounced but opposing changes in the levels of mRNA encoding AChE and those encoding ChAT or VAcHT following both stress and DFP.

While AChE mRNA levels were markedly increased as  
10 compared with controls, the levels of ChAT and VAcHT mRNAs were prominently reduced (Figure 3A) under both experimental conditions. These changes in gene expression lagged behind elevated c-fos levels by up to 20 minutes (Figure 3A), consistent with the idea that c-fos plays a  
15 role in modulating cholinergic gene expression and that c-fos may either enhance or suppress gene transcription, depending on its interactions with additional factors. Changes in the levels of mRNA encoding synaptophysin, L-type Ca++ channel or glyceraldehyde-phosphodehydrogenase  
20 were not observed.

These data therefore implied that acute cholinergic stimulation promotes selective bi-directional changes in gene regulation that act to reduce the bioavailability of acetylcholine through suppressed synthesis/packaging and  
25 enhanced hydrolysis of neurotransmitter. Thus, they predicted a delayed phase of reduced neuronal excitability following both stress and AChE inhibition.

To test the hypothesis that acetylcholinesterase inhibitors mediate both acute and delayed phases of  
30 cholinergic activity in the brain, electrophysiological recordings were performed in sagittal hippocampal brain slices. Following one hour exposure to DFP, and under a wide range of stimuli intensities, recordings in the CA1 region of the hippocampus revealed increased amplitude,  
35 rate of rise and paired-pulse facilitation duration in

response to orthodromic stimulation of the CA2/CA3 region of stratum oriens, which contains cholinergic fibers (Figure 3B). The non-hydrolyzable ACh-analog carbamylcholine induced parallel, dose-dependent increases in signal (Figure 4A), suggesting a common pathway for the acute hyperactivity elicited by direct receptor activation and that promoted by cholinesterase inhibition. However, when AchE inhibition was extended to 3 hours by continuous perfusion with physostigmine, the enhanced responsiveness of cholinergic pathways to stimulation was prominently muted, approaching that displayed by control slices. This observation allowed the identification of a transient, early phase of excitability and a delayed phase of suppression. Notably, both phases of physostigmine-mediated hyperactivity could be blocked by adding the selective muscarinic antagonist atropine to the perfusion solution during the early phase. This experiment indicated that the late phase of depressed activity depended on a prior, early phase of acute stimulation, and that activation of muscarinic receptor receptors plays an indispensable role in initiating this chain of events. Paired-pulse facilitation examined under the same experimental conditions demonstrated a complementary pattern of hyperexcitability followed by suppressed activity (Fig. 4D). Thus, these data show that a rapid, transient phase of cholinergic activation stimulates a delayed feedback pathway that works to restore basal brain activity and that this regulatory mechanism is controlled by modulated synthesis of the proteins mediating cholinergic neurotransmission.

Since the c-fos gene contains a  $\text{Ca}^{++}$ -responsive element [Ghosh et al, 1994], it appears that intracellular accumulation of calcium should play a role in translating the transient phase of cholinergic

hyperactivation into changes in gene regulation. Indeed, the calcium chelator BAPTA-AM prevented enhanced paired-pulse facilitation (Fig. 5A) and both BAPTA-AM and the sodium channel blocker tetrodotoxin (TTX) attenuated the changes in c-fos and ChAT mRNA levels mediated by AChE inhibition (Fig. 5B). These observations demonstrated a direct correlation between neuronal activity,  $Ca^{++}$ -mediated second messenger pathways, and modulations in cholinergic gene expression.

Acetylthiocholine hydrolysis in homogenates from microdissected brain regions at various times following stress treatment revealed 2-3 fold increases in AChE activity within 50 minutes after stress in both cortex and hippocampus, but not cerebellum (Fig. 6A), in line with findings of others [Tsakiris et al, 1993]. Surprisingly, AChE activity in neocortex of animals exposed to a single stress session remained significantly higher than that observed in control mice for over 80 hours ( $P < 0.005$ , 2-tailed t test). In contrast, hippocampal AChE activity was elevated for only 4 hours, following which period it had stably dropped back close to control values.

Electrophoretic separation under non-denaturing conditions revealed the presence of novel, fast-migrating AChE form(s) in brains of stressed mice (Fig. 6B). This pattern of gel migration corresponded closely to that of the highly hydrophilic, monomeric, secreted form of catalytically active readthrough AChE produced in heterologous expression systems [Seidman et al, 1995]. The minor readthrough AChEmRNA species was detected in brain and in several tumor cell lines [Karpel et al, 1994], but its protein product had never been unequivocally identified in vivo and its physiological significance is yet unclear.

Following either stress or exposure to AChE inhibitors, a pronounced increase was observed by RT-PCR in the level of the mRNA encoding readthrough AChE in which intron I4 is retained in the mature transcript (Fig. 7A,B). In contrast, neither the transcript containing alternative 3' exon 6 (E6) and encoding the dominant synaptic form of the enzyme, nor that carrying alternative E5 and encoding the hematopoietic form of AChE displayed detectable changes in their patterns of expression (Fig. 7A,B). Stress, via neuronal excitation, thus mediates not only enhanced transcription, but also modified alternative splicing from the ACHE gene, leading exclusively to de novo synthesis of the unique readthrough AChE isoform.

High resolution in situ hybridization on cortical sections revealed striking qualitative and quantitative differences between control and pyridostigmine-treated animals in the expression of readthrough ACHE mRNA. In controls, signals were relatively weak and restricted to somata of neurons in cortical layers 2 and 5. In contrast, both somata and apical dendrites of neurons from all cortical layers were intensely labeled following exposure to pyridostigmine (Fig. 7B). However, an exon 6-specific probe revealed similar levels of labeling intensities for E6-AChE mRNA in somata of neurons in layers 2 and 3 of the parietal cortex of control and pyridostigmine-treated mice (Fig. 7). That otherwise non-AChE expressing cells begin producing large amounts of a secretable, non-synaptic form of AChE following acute cholinergic stimulation suggests non-cholinergic involvement, implicating the non-catalytic activities of the AChE protein [Small et al, 1995; Jones et al, 1995; Layer and Willbold, 1995].

These findings demonstrate that the sequence of events common to the brain's responses to acute stress

and to cholinesterase inhibitors initiates with a brief phase of neuronal excitability. This triggers within a few minutes rapid induction of c-fos that mediates hours -long selective regulatory effects on the transcription activities of several genes involved directly or indirectly in acetylcholine metabolism. This rapidly floods the intercellular spaces with acetylcholine-hydrolyzing potential, which can play a crucial role in short-term quieting of brain activity following a traumatic experience.

#### EXAMPLE 4

##### Effect of swim stress on the blood brain barrier to horseradish peroxidase

Forced swim induced stress has been shown to increase brain penetration of Evans Blue (Example 2). However, a detailed evaluation of the anatomical distribution stress induced perturbations in BBB within the brain was not explored. This Example uses horseradish peroxidase (HRP) to study the effects of stress on the BBB and anatomical distribution of the dye due to stress (Figure 14A). Horseradish peroxidase also has been used to study changes in the BBB, often in parallel to Evan's Blue [Broadwell et al, 1982; Wijsman et al., 1993]. However, unlike Evans Blue, a permanent color product can formed by the histochemical reaction of HRP with diaminobenzidine. Since direct histochemical staining of exogenous HRP may be difficult to distinguish from endogenous peroxidases we have employed an antibody specific to HRP that enables immunohistochemical localization of HRP. This immunohistochemical protocol also provides a permanent color.

##### Methods

Male mice were assigned to two groups: The experimental group (n=3) was exposed to swim stress (2. x 4 minute



swims with 4 minute rest between swims as described herein above) prior to HRP injection and the control group (n=3) remained in the home cage prior to HRP injection.

- 5 90 mg HRP was dissolved in saline and then diluted 1:1 with 0.2% solution of Evans Blue (as a tracer). 0.1 ml HRP was injected into the tail vein under pentobarbital anesthesia. Mice were sacrificed 15 minutes after injection of HRP.
- 10 Brains were fixed by transcardial perfusion of 4% paraformaldehyde in 0.1M phosphate buffered saline, pH 7.4 at room temperature, which also contained 4% sucrose [Shoham et al, 1997]. Duration of perfusion was 8-10 minutes. A sagittal cut was made to separate the two
- 15 hemispheres, and the tissue cut into coronal blocks and immersed in the same fixative as in the perfusion but at ice temperature. After 24 hours, the tissue was transferred to 10% sucrose in 0.1M PBS.
- 20 For immunohistochemical staining, 30  $\mu$ m floating sections were collected in a cryopreservation buffer and kept at -20°C until processing. The first step of immunohistochemical processing was to quench endogenous peroxidase activity by incubation of brain sections with hydrogen peroxide [Shoham et al, 1997]. Then sections
- 25 were incubated with Rabbit anti HRP from Jackson ImmunoResearch, USA, at a dilution of 1:100, first at room temperature for 1 hour and then overnight refrigerated. Subsequently sections were processed through a standard biotin-extravidin-peroxidase procedure
- 30 in which the final color reaction was produced using DAB as a substrate with the addition of nickel ammonium sulfate [Shoham et al, 1997] and specific areas evaluated: CA2 (I), CA3 (II), Piriform cortex (III), hypothalamus (IV) and chorioid plexus (V) as shown on
- 35 Figure 14A.

The forced swimming stress increased penetration of HRP into brain (Table 2, Figure 14B). In both stressed and control mice, staining in blood vessels is expected after intravenous administration and this was confirmed in both stressed and unstressed mice. Staining in choroid plexus and ventromedial hypothalamus is also predictable since these areas are less protected by a BBB. However, even in hypothalamus, in the stressed animal staining spread from the ventricular wall to individual cells of the arcuate nucleus of hypothalamus. Based on their morphology, at least some of these cells were neurons.

With regard to other brain regions, the hippocampus had the highest number of stained cells. These cells appeared to be interneurons. The fact that in the control mouse the only stained cells appeared in the CA3 subregion of hippocampus and very close to the lateral ventricle suggests the spread of HRP first to the cerebrospinal fluid and then into brain regions. In the stressed mouse, stained cells appeared in all subregions of the hippocampus. Furthermore, dendrites of pyramidal cells from CA1 were stained.

Staining of white matter such as the corpus callosum may represent diffusion of HRP from CSF into brain tissue. However, staining of piriform cortex and retrosplenial cortex may involve more than diffusion from CSF since theoretically the entire cortex is surrounded by CSF and should have been stained if diffusion was the only mechanism. The differential staining of piriform and retrosplenial cortex may be related to reactivity of these brain regions in response to some stressful situations. In a different study using these two brain regions displayed increased uptake of radioactive 2-deoxyglucose following swim stress [Duncan et al, 1993]. Thus, within the context of swim-stress, the pattern of

the staining observed in this Example matches the pattern of induced metabolic activity.

In other stress-inducing situations, the piriform and retrosplenial cortices have also been exhibit  
5 increased expression of c-fos mRNA [Imaki et al, 1993]. However, the pattern of brain regions which react to stress varies with the stress-inducing situation. Thus, for example, if stress is induced by foot-shock or by a stimulus associated with foot-shock, the central nucleus  
10 of the amygdala increases its metabolic activity [Campeau et al, 1991]. If stress is induced by immobilization stress, then metabolic activity is increased in the paraventricular nucleus of thalamus and hypothalamus and in the habenula but not in the amygdala [Chastrette et  
15 al, 1991]. In contrast, in the swim stress paradigm there is no increase in 2-deoxyglucose uptake or in FOS expression in the central nucleus of the amygdala or in the paraventricular nucleus of the hypothalamus [Duncan et al, 1993]. Thus, the absence of HRP staining in these  
20 regions in these stressed mice is consistent with the anatomical pattern of activation unique to swim stress.

Together, these data provide further progress in mapping the disruption of the BBB induced by acute stress, and offers indications for the brain regions most  
25 likely to be affected by stress-induced perturbations of BBB integrity. As such, they will serve as a basis to evaluate the development pharmacological strategies for transient opening of the BBB based on the stress paradigm. Moreover, the strong HRP staining of the  
30 hippocampus following forced swimming indicates that this area brain region should be used for drug delivery protocols using this approach.

## EXAMPLE 5

Computerized Tomography (CT) Reveals Disruption  
Of The BBB IN Patients With Neuropathologies  
With Associated Cholinergic Changes

5

CT is used to detect brain tumors by visualizing their contours, using an electron-dense probe. CT scans are taken before and after probe injections and intensified signals are sought for by automated  
10 measurements of electron density. Neuwelt et al [1980b, 1979] has used CT to monitor chemotherapy delivery in patients with brain tumors and using osmotic disruptions. Therefore for the present invention, this same technology is used to determine if the BBB is disrupted in patients  
15 who do not have brain tumors and can be correlated with cholinergic changes as disclosed by the present invention. It can test where the disruption takes place and provides a quantifiable method to establish its intensity in response to the stress-mimicking treatments  
20 and agents of the present invention.

It is expected that in a control patient, with no tumor, the CT scan will be normal and there will be no penetrance of the electron dense dye into the CNS. 30 scans of normal patients were taken and no disruption of  
25 the BBB was seen (Figure 12A-F). Average signal values were significantly lower than standard deviations in five brain regions (posterior fossa, pons, thalamus, white matter and frontal left cortex). These findings differed from those in the neck's soft tissue, which is not  
30 protected by the BBB, where mean signal values were considerably higher than those in brain regions (13.5 as compared with 4.0, -1.2, 3.1, 1.1 and 5.0, for the above regions respectively) and standard deviation close to signal value.

Parallel tests in 30 neurological patients revealed a totally different picture. Signals (percent enhanced contrast as compared with scans taken prior to probe injection) were essentially similar to those of the control group in the neck tissue and in the posterior fossa, considered not to be close to the BBB border. In contrast, signals in pons, white matter and frontal cortex were both increased (by 2-7 fold) and diversified (i.e. displayed large standard deviations) than those in control subjects (Figure 13).

In the neurologic patients, CSF total protein levels and activities of BChE and AChE were measured as well. A positive correlation was found between probe signal in brain CT to total protein levels measured in the CSF. Patients with normal levels of CSF protein levels had probe signals similar to that found in the controls. Patients with abnormally high protein levels had also abnormally high probe signals, indicating a BBB disruption. It appears likely that the BBB disruption allowed serum protein to enter the CSF. Also there was clear correlation between the BChE and AChE activities, with most patients grouped together and having close values for both enzymes (0-0.5 mOD/min for acetylcholine or butyrylcholine hydrolysis). However, five patients had considerably higher ChE activities in their CSF, either because of excessive synthesis or due to penetrance from the circulation. Moreover, these patients were the patients in which the brain signals had increased the most.

#### EXAMPLE 6

##### Pharmacologically-induced penetration of the blood-brain barrier

As shown in Examples 2 and 4 herein above, studies of penetration of blood-brain barrier disruption have in

the past depended on injection of traceable agents, such as dyes, with the measurement of the agent in the CNS determining how much disruption of the BBB had occurred. However, these agents either are measured in a post-mortem analysis of the brain or using CT scans (Example 5). It would be useful to have a more rapid and sensitive assay in animal models for use in screening BBB integrity.

A rapid physiological assay has been developed based on the reduction in body temperature induced in mice by centrally acting acetylcholinesterase (ACHE) inhibitors. In the assay pyridostigmine is used. Pyridostigmine is generally excluded from the CNS (see Example 1). However, perturbations leading to an opening/disruption in the BBB allow increased access of pyridostigmine to the CNS as shown in Example 1. This increased access of pyridostigmine in the CNS leads to reduction in body temperature which can be monitored. Therefore the assay requires the administration of pyridostigmine together with a compound (or combinations of compounds) to test the efficacy of the compound to disrupt (open) the BBB to allow (facilitate) passage of pyridostigmine across the BBB. The body temperature is then monitored for several hours to determine whether the BBB has opened and the duration. This method also allows for the determination of optimal doses of compounds being tested.

Adult, female FVB/N mice (3 per group) were injected intraperitoneally (ip) with freshly prepared pyridostigmine (0.6 mg/kg body weight) alone or together with the drug or drug combinations to be tested. In this Example dopamine (DA, 1.0 mg/kg) an  $\alpha$  adrenergic agonist and propranolol (0.04 mg/kg) a  $\beta$  adrenergic antagonist or the combination of DA and propranolol were tested. Rectal body temperature was monitored for 180 minutes at 20 minute intervals. A single temperature measurement was

made 25 minutes prior to the injection to acclimate the animals to the procedure.

As shown in Figure 15, pyridostigmine alone or together with propranolol induced a 1 to 1.5°C reduction in body temperature within 40 minutes. Body temperature returned to normal by 80 minutes post injection. Coinjection with DA enhanced the reduction by approximately 0.5°C. However, coadministration of DA and propranolol effected a synergistic effect on pyridostigmine permeability of the BBB. The combination induced reduction in body temperature of approximately 2.5°C in the same time window.

The simultaneous activation of  $\alpha$  adrenergic receptors together with blocking of  $\beta$  adrenergic receptors effects a synergistic effect on BBB permeability.

Throughout this application, various publications, including United States patents, are referenced by author and year and patents by number. Full citations for the publications are listed below. The disclosures of these publications and patents in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.

The invention has been described in an illustrative manner, and it is to be understood that the terminology which has been used is intended to be in the nature of words of description rather than of limitation.

Obviously, many modifications and variations of the present invention are possible in light of the above teachings. It is, therefore, to be understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically described.

Table 1

Readthrough AChE-I4, the I4 sequence is underlined.

Met Arg Pro Pro Gln Cys Leu Leu His Thr Pro Ser Leu Ala Ser Pro  
 Leu Leu Leu Leu Leu Leu Trp Leu Leu Gly Gly Gly Val Gly Ala Glu  
 Gly Arg Glu Asp Ala Glu Leu Leu Val Thr Val Arg Gly Gly Arg Leu  
 Arg Gly Ile Arg Leu Eys Thr Pro Gly Gly Pro Val Ser Ala Phe Leu  
 Gly Ile Pro Phe Ala Glu Pro Pro Met Gly Pro Arg Arg Phe Leu Pro  
 Pro Glu Pro Lys Gln Pro Trp Ser Gly Val Val Asp Ala Thr Thr Phe  
 Gln Ser Val Cys Tyr Gln Tyr Val Asp Thr Leu Tyr Pro Gly Phe Glu  
 Gly Thr Glu Met Trp Asn Pro Asn Arg Glu Leu Ser Glu Asp Cys Leu  
 Tyr Leu Asn Val Trp Thr Pro Tyr Pro Arg Pro Thr Ser Pro Thr Pro  
 Val Leu Val Trp Ile Tyr Gly Gly Gly Phe Tyr Ser Gly Ala Ser Ser  
 Leu Asp Val Tyr Asp Gly Arg Phe Leu Val Gln Ala Glu Arg Thr Val  
 Leu Val Ser Met Asn Tyr Arg Val Gly Ala Phe Gly Phe Leu Ala Leu  
 Pro Gly Ser Arg Glu Ala Pro Gly Asn Val Gly Leu Leu Asp Gln Arg  
 Leu Ala Leu Gln Trp Val Gln Glu Asn Val Ala Ala Phe Gly Gly Asp  
 Pro Thr Ser Val Thr Leu Phe Gly Glu Ser Ala Gly Ala Ala Ser Val  
 Gly Met His Leu Leu Ser Pro Pro Ser Arg Gly Leu Phe His Arg Ala  
 Val Leu Gln Ser Gly Ala Pro Asn Gly Pro Trp Ala Thr Val Gly Met  
 Gly Glu Ala Arg Arg Arg Ala Thr Gln Leu Ala His Leu Val Gly Cys  
 Pro Pro Gly Gly Thr Gly Gly Asn Asp Thr Glu Leu Val Ala Cys Leu  
 Arg Thr Arg Pro Ala Gln Val Leu Val Asn His Glu Trp His Val Leu  
 Pro Gln Glu Ser Val Phe Arg Phe Ser Phe Val Pro Val Val Asp Gly  
 Asp Phe Leu Ser Asp Thr Pro Glu Ala Leu Ile Asn Ala Gly Asp Phe  
 His Gly Leu Gln Val Leu Val Gly Val Val Lys Asp Glu Gly Ser Tyr  
 Phe Leu Val Tyr Gly Ala Pro Gly Phe Ser Lys Asp Asn Glu Ser Leu  
 Ile Ser Arg Ala Glu Phe Leu Ala Gly Val Arg Val Gly Val Pro Gln  
 Val Ser Asp Leu Ala Ala Glu Ala Val Val Leu His Tyr Thr Asp Trp  
 Leu His Pro Glu Asp Pro Ala Arg Leu Arg Glu Ala Leu Ser Asp Val  
 Val Gly Asp His Asn Val Val Cys Pro Val Ala Gln Leu Ala Gly Arg  
 Leu Ala Ala Gln Gly Ala Arg Val Tyr Ala Tyr Val Phe Glu His Arg  
 Ala Ser Thr Leu Ser Trp Pro Leu Trp Met Gly Val Pro His Gly Tyr  
 Glu Ile Glu Phe Ile Phe Gly Ile Pro Leu Asp Pro Ser Arg Asn Tyr  
 Thr Ala Glu Glu Lys Ile Phe Ala Gln Arg Leu Met Arg Tyr Trp Ala  
 Asn Phe Ala Arg Thr Gly Asp Pro Asn Glu Pro Arg Asp Pro Lys Ala  
 Pro Gln Trp Pro Pro Tyr Thr Ala Gly Ala Gln Gln Tyr Val Ser Leu  
 Asp Leu Arg Pro Leu Glu Val Arg Arg Gly Leu Arg Ala Gln Ala Cys  
 Ala Phe Trp Asn Arg Phe Leu Pro Lys Leu Leu Ser Ala Thr Gly Met  
Gln Gly Pro Ala Gly Ser Gly Trp Glu Glu Gly Ser Gly Ser Pro Pro  
Gly Val Thr Pro Leu Phe Ser Pro



Table 2

The following Table summarizes the histochemical data distribution of HRP-immunohistochemical staining for the animals from which the sections depicted in Figure 14 were taken:

Brain region	non-stressed control	stressed
Choroid plexus	+	+
HRP in blood vessels	+	+
Medial hypothalamus (arcuate nucleus)	+ (diffuse staining)	+ (diffuse staining plus staining of cells)
Piriform cortex	diffuse staining restricted to the tip of the cortex	diffuse staining but covering a greater area than in C3
Retrosplenial cortex	diffuse staining at the upper tip.	diffuse staining but covering a greater area than in C3
Hippocampus, CA3	diffuse staining plus staining of cells	diffuse staining plus staining of cells (more than in C3)
Hippocampus, CA1-2	no staining	staining of cells
Corpus callosum	little staining	extensive staining of fibers

REFERENCES

- Andres et al. (1997). ACHE transgenic mice display embryonic modulations in spinal cord CHAT and neurexin gene expression followed by late-onset neuromotor deterioration. *Proc. Natl. Acad. Sci. USA* 94, 8173.
- Bausero, et al (1993) Identification and analysis of the human choline acetyltransferase gene promoter. *Neuroreport* 4:287.
- Ben Aziz-Aloya et al (1993) Expression of a human acetylcholinesterase promoter-reporter construct in developing neuromuscular junctions of *Xenopus* embryos. *Proc. Natl. Acad. Sci. U.S.A.*, 90, 2471-2475.
- Ben-Nathan, et al, 1991. Stress-induced neuroinvasiveness of a neurovirulent noninvasive Sindbis virus in cold or isolation subjected mice. *Life Sci.* 48:1493-1500.
- Betz et al, 1994. Blood-Brain-Cerebrospinal Fluid Barriers. Chapter 32 in *Basic Neurochemistry* (5th Edition, Eds Siegel, Albers, Agranoff, Molinoff), pp 681-701.
- Bickel, et al., 1993. Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery. *Proc. Natl. Acad. Sci. USA* 90(7)2618-2622
- Blick, et al. Acute behavioral toxicity of pyridostigmine or soman in primates. *Toxicol. Appl. Pharmacol.* 126, 311-318 (1994).
- Borland, et al., Studies on the possible central and peripheral effects in man of a cholinesterase inhibitor (pyridostigmine). *Hum. Toxicol.* 4, 293-300 (1985).
- Breaking the Brain Barrier in *The Economist*, January 4, 1997.
- Bremner et al (1995) MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder. *Am. J. Psychiatry* 152:973
- Brem et al., 1993. Polymers as controlled drug delivery devised for the treatment of malignant brain tumors. *Eur. J. Pharm. Biopharm* 39:2-7.

Broadwell et al. Morphologic effect of dimethyl sulfoxide on the blood-brain barrier. Science 217:164-166, 1982.

Brust, Blood-brain-barrier transport under different physiological and pathophysiological circumstances including ischemia. Exp.Pathol. 42, 213-219 (1991).

Campeau et al. Induction of c-fos proto-oncogene in rat amygdala during unconditioned and conditioned fear. Brain Res. 565:349-352, 1991.

Chastrette et al. Effects of daytime and night-time stress on Fos-like immunoreactivity in the paraventricular nucleus of the hypothalamus, the habenula, and the posterior paraventricular nucleus of the thalamus. Brain Res. 563:339-344, 1991.

Deyi, et al., The inhibition and protection of cholinesterase by physostigmine and pyridostigmine against soman poisoning in vivo. Fundam. Appl. Toxicol. 1, 217-221 (1981).

Diruhumber, et al., The protection of primates against soman poisoning by pretreatment with pyridostigmine. J. Pharmacol. 31, 295-299 (1979).

Duncan et al. Topographic patterns of brain activity in response to swim stress: Assessment by 2-deoxyglucose uptake and expression of Fos-like immunoreactivity. J. of Neurosci. 13:3932-3943, 1993.

Ekstrom, et al., Promoter elements and transcriptional regulation of the acetylcholinesterase gene. DNA.Cell.Biol. 12, 63-72 (1993).

Eiden and Erickson, The Vesicular acetylcholine transporter and the VAChT/ChAT gene locus". J. Neurochem, in press.

Ennis and Shipley, 1992. Tonic activation locus coeruleus neurons by systemic or intracoerulear microinjection of an irreversible acetylcholinesterase inhibitor: Increased discharge rate and induction of c-fos. Exp. Neurol. 118:164-177.

Friedman et al. (1996). Pyridostigmine brain penetration under stress enhances neuronal excitability and induces

early immediate transcriptional response. *Nature Medicine* 2, 1382-1385.

Friedman and Gutnick, (1989) Intracellular calcium and control of burst generation in neurons of guinea-pig neocortex in vitro. *Europ. J. Neurosci.* 1:374-381.

Ghosh, et al (1994) Calcium regulation of gene expression in neuronal cells. *J. Neurobiol.* 25, 294-303.

Glickson, et al. The influence of pyridostigmine on human neuromuscular functions - studies in healthy human subjects. *Fund. Appl. Toxicol.* 16, 288-298 (1991).

Goldstein and Betz, 1986. The Blood-Brain Barrier. *Scientific American*, September, 1986, pp 74-83.

Gurvits, et al (1993) Neurological status of vietnam veterans with chronic posttraumatic stress disorder. *J. Neuropsychiatry Clin. Neurosci.* 5:183

Harik and Kalaria, Blood-brain-barrier abnormalities in Alzheimer's disease. *Ann. New York Acad. of Sci.* 640, 47-52 (1991).

Imaki T et al. Intracerebroventricular administration of corticotropin-releasing factor induces c-fos mRNA expression in brain regions related to stress response: comparison with pattern of c-fos mRNA induction after stress. *Brain Res.* 616:114-125, 1993.

Imperato, et al, 1991. Changes in brain dopamine and acetylcholine release during and following stress are independent of the pituitary-adrenocortical axis. *Brain Res.* 538:111-117.

Jones et al (1995) The effect of acetylcholinesterase on outgrowth of dopaminergic neurons in organotypic slice culture of rat mid brain. *Cell Tissue Res.* 279: 323-330

Karpel, et al (1994) Expression of three alternative acetylcholinesterase messenger RNAs in human tumor cell lines of different tissue origins. *Exptl. Cell Res.* 210, 268-277

Karpel, et al (1996) Overexpression of alternative human acetylcholinesterase forms modulates process extensions in cultured glioma cells. *J. Neurochem.*, 66, 114-123.

Lallement, et al, (1991). Effects of soman-induced seizures on different extracellular amino acid levels and on glutamate uptake in rat hippocampus. *Brain Res* 563(1-2):234-240.

Layer and Willbold, (1995). Novel functions of cholinesterases in development, physiology and disease. *Prog. Histochem. Cytochem.* 29:1-99.

Lewis et al (1967). Conformation from choline acetylase analyses of a massive cholinergic innervation to the rathippocampus. *J. Physiol. Lond.* 191, 215-224.

McEwen and Sapolsky, Stress and cognitive function. *Curr. Opin. in Neurobiol.* 5, 205-216 (1995).

Melia, et al, Induction and habituation of immediate early gene expression in rat brain by acute and repeated restraint stress. *J. Neurosci.* 14, 5929-5938 (1994).

Neuwelt and Fraenkel, 1980a. Is there a therapeutic role of blood-brain barrier disruption? *Annals Int Med* 93(1):137-139 (editorial note).

Neuwelt et al, 1980b. The use of enhanced comouterized tomography to evaluate osmotic blood brain barrier disruption. *Neurosurgery* 6:49-56.

Neuwelt et al, 1979. Osmotic blood-brain barrier disruption: computerized tomographic monitoring of chemotherapeutic agent delivery. *J Clin Inves.* 64:684-688.

Neville, et al., Anionic site interactions in human butyrylcholinesterase disrupted by two single point mutations. *J. Biol. Chem.* 265, 20735-20738 (1990).

Pardridge, et al., 1992. Blood-brain barrier and new approaches to brain drug delivery. *West J. Med.* 156(3) 281-286

Pardridge, 1992. Recent Developments in peptide drug delivery to the brain. *Pharm. Toxicol.* 71(1):3-10

Petralli et al, 1991. Effect of an anticholinesterase compound on the ultrastructure and function of the rat blood-brain barrier: a review and experiment. *J Submicrosc Cytol Pathol* 23(2):331-338.

Putnam, 1992. Using hypnosis for therapeutic abreactions. *Psychiatr. Med.* 10(1):51-65.

Rachinsky, et al., Molecular cloning of mouse acetylcholinesterase: tissue distribution of alternatively spliced mRNA species. *Neuron*. 5, 317-327 (1990).

Rosenstock et al (1991) Chronic central nervous system effects of acute organophosphate pesticide intoxication. *Lancet*. 338, 223-227

Sapolsky, (1996) Why stress is bad for your brain. *Science* 273:749-750.

Seidman et al. (1995) Synaptic and epidermal accumulations of human acetylcholinesterase is encoded by alternative 3'-terminal exons. *Mol. Cell. Biol.* 15, 2993-3002.

Shoham S et al. Nitric oxide synthase in ventral forebrain grafts and in early ventral forebrain development. *Dev. Brain Res.* 99:155-166, 1997.

Small et al (1995) Cholinergic regulation of neurite outgrowth from isolated chick sympathetic neurons in culture. *J. Neurosci.* 15:144-151

Sharma, et al, 1991. Increased blood-brain barrier permeability following acute short-term swimming exercise in conscious normotensive young rats. *Neurosci. Res.* 10:211-221.

Sharabi, et al. Survey of symptoms following intake of pyridostigmine during the Persian gulf war. *Isr. J. Med. Sci.* 27, 656-658 (1991).

Solomon, et al, 1992. The efficacy of treatments for posttraumatic stress disorder. An empirical review. *JAMA* 268(5):633-638.

Spiegel, 1992. The use of hypnosis in the treatment of PTSD. *Psychiatr. Med.* 10(4):21-30.

Taylor, Cholinergic agonists, Anticholinesterase Agents. In: The Pharmacological Basis of Therapeutics. 8th Ed., (Eds: Gilman A.G., Rall T.W., Nies A.S. & Taylor P.), pp. 122-130, 131-147 (1990). Pergamon Press, New York.

Tsakiris and Kontopoulos (1993) Time changes in Na<sup>+</sup>, K<sup>+</sup>-ATPase, Mg<sup>++</sup>-ATPase, and acetylcholinesterase activities in the rat cerebrum and cerebellum caused by stress. Pharmacol. Biochem. Behav. 44:339-42.

Tuomanen, 1993. Breaching the blood-brain barrier. Scientific American February 1993, 268:80-84.

Uyama, et al. Quantitative evaluation of vascular permeability in the gerbil brain after transient ischemia using Evans blue fluorescence. J. Cerebral Blood Flow and Metabolism, 8, 282-284 (1988).

Wijsman JA et al. Heat stress affects blood-brain barrier permeability to horseradish peroxidase in mice. Acta Neuropathol. 86:49-54, 1993.

CLAIMS

What is claimed is:

1. A pharmaceutical composition for facilitating passage of compounds through the blood-brain barrier comprising

ACHE-I4 readthrough (SEQ ID No:1) splice variant or analogues thereof and a pharmaceutically acceptable carrier.

2. A pharmaceutical composition for facilitating passage of compounds through the blood-brain barrier comprising

I4 peptide (SEQ ID No:2) and analogues thereof and a pharmaceutically acceptable carrier.

3. A pharmaceutical composition for facilitating passage of compounds through the blood-brain barrier comprising at least one of

ACHE-I4 readthrough (SEQ ID No:1) splice variant, I4 peptide, adrenaline, atropine, dopamine or an adrenergic combination and a pharmaceutically acceptable carrier.

4. A pharmaceutical composition as set forth in claim 3 wherein said adrenergic combination consists of dopamine and propranolol and a pharmaceutically acceptable carrier.

5. The pharmaceutical composition as set forth in claims 1 through 4 further including a compound to be passaged through the blood-brain barrier.

6. A method for administering a compound to the central nervous system of a mammal comprising



subjecting a mammal to a stress-mimicking means which facilitates disruption of the blood-brain barrier and administering a compound whereby said compound is enabled to passage through the disrupted blood-brain barrier into the central nervous system.

7. The method of claim 6 wherein said mammal is a human patient in need of a compound to be administered to the central nervous system.

8. The method of claim 6 wherein said stress-mimicking means is at least one of hypnosis, adrenaline, atropine, dopamine, adrenergic combination, ACHE-I4 (SEQ ID No:1) or I4 peptide (SEQ ID No:2).

9. The method of claim 6 wherein said administering step is simultaneous with said subjecting to a stress-mimicking-inducing means step.

10. The method of claim 6 wherein said administering step follows said subjecting to a stress-mimicking means step within a period of time during which the blood-brain barrier is disrupted by said stress-mimicking means.

11. A method of inducing a stress-mimicking treatment in a mammal whereby the blood-brain barrier is disrupted enabling passage of a compound through the blood-brain barrier comprising using at least one of hypnosis, administering adrenaline, administering atropine, administering dopamine, administering an adrenergic combination, administering ACHE-I4 (SEQ ID No:1) or administering I4 peptide (SEQ ID No:2).

12. The method of claim 11 wherein said mammal is a human patient in need of a compound to be administered to the central nervous system.

13. A pharmaceutical composition for facilitated administration of a drug through the blood-brain barrier comprising

said drug in combination with a stress-mimicking inducing agent or treatment and a pharmaceutically acceptable carrier.

14. The method of claim 13 wherein said stress-inducing agent or treatment is hypnosis, adrenaline, atropine, dopamine, adrenergic combination, ACHE-I4 (SEQ ID No:1) or I4 peptide (SEQ ID No:2).

15. The method of claim 14 wherein the adrenergic combination is an  $\alpha$  adrenergic agonist and a  $\beta$  adrenergic antagonist.

16. The method of claim 15 wherein the  $\alpha$  adrenergic agonist is dopamine and the  $\beta$  adrenergic antagonist is propranolol.


17. A physiological method for determining the efficacy of a compound to increase the permeability of the blood-brain barrier to facilitate passage of pyridostigmine across the blood brain barrier comprising

administration of pyridostigmine together with a compound to be tested

monitoring the body temperature for reduction whereby an greater reduction in body temperature compared to controls indicates that the compound to be tested has increased the permeability of the blood-brain barrier.



1/14

**Fig-1**




**Fig-2**


2/14

Fig- 3AFig- 3B

SUBSTITUTE SHEET (RULE 26)



3/14



SUBSTITUTE SHEET (RULE 26)

4/14

Fig-5A





Fig-5B



5/14

Fig-6A







Fig-6B



6/14



**Fig-7A**



**Fig-7B**



7/14




Fig-8B




Fig-8D





Fig-8A




Fig-8C


8/14




**Fig-9C**




**Fig-9B**




**Fig-9A**



**Fig-9F**





**Fig-9E**




**Fig-9D**

9/14

Fig-10AFig-10B

10/14

Fig-11

11/14




Fig-12C




Fig-12F




Fig-12B




Fig-12E




Fig-12A





Fig-12D

12/14



**Fig-13**

13/14

Fig-14A






Fig-14B



14/14

**Fig-15**



# INTERNATIONAL SEARCH REPORT

Inten 1al Application No  
PCT/US 97/21696

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61K38/46 A61K31/135 A61K31/46

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 414 568 A (WASHINGTON UNIVERSITY) 27 February 1991 see the whole document ---	3-16
A	WO 95 23158 A (YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSAL) 31 August 1995 see the whole document ---	1-17
A	EP 0 364 584 A (KI NII FARMAKOLOGII TOKSIKOLOG) 25 April 1990 see the whole document ---	1-17
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

15 May 1998

Date of mailing of the international search report

24.06.1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Moreau, J

## INTERNATIONAL SEARCH REPORT

Inter. nat. Application No

PCT/US 97/21696

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>FRIEDMAN, ALON ET AL: "Pyridostigmine brain penetration under stress enhances neuronal excitability and induces early immediate transcriptional response" NAT. MED. (N. Y.) (1996), 2(12), 1382-1385, XP002065074 see the whole document -----</p>	1-17

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 97/21696

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 6-16 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.  
Although claim 17 is directed to a diagnostic method practised on the
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

page 1 of 2

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 97/21696

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

page 2 of 2

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Although claims 6-16 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.  
Although claim 17 is directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Inten val Application No

PCT/US 97/21696

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 414568	A	27-02-1991	US 4988710 A	29-01-1991
			US 5011853 A	30-04-1991
WO 9523158	A	31-08-1995	AU 2096395 A	11-09-1995
			EP 0750627 A	02-01-1997
EP 0364584	A	25-04-1990	WO 8910124 A	02-11-1989

Form PCT/ISA/210 (patent family annex) (July 1992)